FrancophonIA/ELRC3.0 huggingface dataset:
English: There is no difference in response to Irbesartan Hydrochlorothiazide BMS, regardless of age or gender.
Slovenian: Odziv na zdravljenje z zdravilom Irbesartan Hydrochlorothiazide BMS ni odvisen od starosti ali spola.
English: Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Slovenian: Ledvična okvara: pri bolnikih z ledvično okvaro in pri tistih na hemodializi farmakokinetični parametri irbesartana niso bistveno spremenjeni.
English: Red and yellow ferric oxides Carnauba wax
Slovenian: Rdeči in rumeni železov oksid karnauba vosek
English: Children should not take Irbesartan Hydrochlorothiazide BMS Irbesartan Hydrochlorothiazide BMS should not be given to children under 18 years of age.
Slovenian: Otroci ne smejo jemati zdravila Irbesartan Hydrochlorothiazide BMS Otroci in mladostniki, mlajši od 18 let, zdravila Irbesartan Hydrochlorothiazide BMS ne smejo jemati.
English: Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Irbesartan Hydrochlorothiazide BMS.
Slovenian: Dodatni podatki o posameznih učinkovinah: poleg zgoraj naštetih neželenih učinkov, ki se lahko pojavijo med uporabo kombiniranega zdravila, se utegnejo med jemanjem zdravila Irbesartan Hydrochlorothiazide BMS pojaviti tudi neželeni učinki, o katerih so predhodno poročali pri jemanju posamezne zdravilne učinkovine.
English: Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with Irbesartan Hydrochlorothiazide BMS.
Slovenian: Tiazidi zmanjšujejo ledvični očistek litija, zato se med zdravljenjem z zdravilom Irbesartan Hydrochlorothiazide BMS poveča nevarnost zastrupitve z litijem.
English: Due to the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide BMS, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.
Slovenian: Če med zdravljenjem z zdravilom Irbesartan Hydrochlorothiazide BMS uživate alkoholne pijače, lahko hidroklorotiazid, ki ga vsebuje zdravilo Irbesartan Hydrochlorothiazide BMS, povzroči omotico v stoječem položaju, še posebej po vstajanju iz sedečega položaja.
English: hepatitis, abnormal liver function
Slovenian: hepatitis, motnje delovanja jeter
English: Irbesartan Hydrochlorothiazide BMS is a combination of two active substances, irbesartan and hydrochlorothiazide.
Slovenian: Zdravilo Irbesartan Hydrochlorothiazide BMS je kombinacija dveh zdravilnih učinkovin, irbesartana in hidroklorotiazida.
English: Irbesartan Hydrochlorothiazide BMS is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Slovenian: Zdravilo Irbesartan Hydrochlorothiazide BMS je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
English: Colestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins;
Slovenian: Holestiramin in holestipol: absorpcija hidroklorotiazida je zaradi anionskih izmenjevalnih smol motena.
English: Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Irbesartan Hydrochlorothiazide BMS (see section 4.5).
Slovenian: Pri hkratnem zdravljenju z diuretiki, ki varčujejo kalij, pripravki s kalijem, nadomestki soli, ki vsebujejo kalij, in zdravilom Irbesartan Hydrochlorothiazide BMS je potrebna posebna previdnost (glejte poglavje 4.5).
English: WHAT IRBESARTAN HYDROCHLOROTHIAZIDE BMS IS AND WHAT IT IS USED FOR
Slovenian: KAJ JE ZDRAVILO IRBESARTAN HYDROCHLOROTHIAZIDE BMS IN ZA KAJ GA UPORABLJAMO
English: Irbesartan Hydrochlorothiazide BMS can be taken once daily, with or without food.
Slovenian: Bolniki lahko zdravilo Irbesartan Hydrochlorothiazide BMS jemljejo enkrat na dan skupaj s hrano ali brez nje.
English: Red and black ferric oxides Carnauba wax
Slovenian: Rdeči in črni železov oksid karnauba vosek
English: Hypotension - Volume-depleted patients: Irbesartan Hydrochlorothiazide BMS has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.
Slovenian: Hipotenzija - zmanjšan intravaskularni volumen: simptomatska hipotenzija se pri bolnikih z zvišanim krvnim tlakom, ki jemljejo zdravilo Irbesartan Hydrochlorothiazide BMS, nimajo pa drugih dejavnikov tveganja za hipotenzijo, pojavi le redko.
English: HOW TO TAKE IRBESARTAN HYDROCHLOROTHIAZIDE BMS
Slovenian: KAKO JEMATI ZDRAVILO IRBESARTAN HYDROCHLOROTHIAZIDE BMS
English: How to store Irbesartan Hydrochlorothiazide BMS Further information
Slovenian: Shranjevanje zdravila Irbesartan Hydrochlorothiazide BMS Dodatne informacije
English: Renal impairment: due to the hydrochlorothiazide component, Irbesartan Hydrochlorothiazide BMS is not recommended for patients with severe renal dysfunction (creatinine clearance < 30 ml/min).
Slovenian: Ledvična okvara: zdravilo Irbesartan Hydrochlorothiazide BMS vsebuje hidroklorotiazid, zato za bolnike s hudo motenim ledvičnim delovanjem (očistek kreatinina < 30 ml/min) ni primeren.
English: When necessary, Irbesartan Hydrochlorothiazide BMS may be administered with another antihypertensive medicinal product (see section 4.5).
Slovenian: Kadar je nujno, smejo bolniki poleg zdravila Irbesartan Hydrochlorothiazide BMS jemati tudi drug antihipertenziv (glejte poglavje 4.5).
English: You can take Irbesartan Hydrochlorothiazide BMS with or without food.
Slovenian: Zdravilo Irbesartan Hydrochlorothiazide BMS lahko jemljete s hrano ali brez nje.
English: Therefore, the combination of lithium and Irbesartan Hydrochlorothiazide BMS is not recommended (see section 4.4).
Slovenian: Sočasna uporaba litija in zdravila Irbesartan Hydrochlorothiazide BMS zato ni priporočljiva (glejte poglavje 4.4).
English: Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road
Slovenian: Imetnik dovoljenja za promet z zdravilom BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road
English: Irbesartan Hydrochlorothiazide BMS will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Slovenian: Zdravnik vam je zdravilo Irbesartan Hydrochlorothiazide BMS predpisal zato, ker se med dosedanjim zdravljenjem vaš krvni tlak ni dovolj znižal.
English: if you get excessive vomiting or diarrhoea if you suffer from kidney problems or have a kidney transplant if you suffer from heart problems if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
Slovenian: Bodite posebno pozorni pri jemanju zdravila Irbesartan Hydrochlorothiazide BMS Obvestite svojega zdravnika, če se karkoli od naslednjega nanaša na vas: če začnete prekomerno bruhati ali dobite hudo drisko če imate težave z ledvicami ali presajeno ledvico če imate težave s srcem če imate težave z jetri če imate sladkorno bolezen če imate eritematozni lupus (znan tudi kot lupus ali sistemski eritematozni lupus) če imate primarni aldosteronizem (stanje, povezano s čezmernim izločanjem hormona aldosterona, kar povzroči zastajanje natrija in posledično zvišanje krvnega tlaka)
English: Renal artery stenosis - Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists.
Slovenian: Stenoza ledvične arterije - renovaskularna hipertenzija: pri bolnikih z obojestransko zožitvijo ledvičnih arterij ali zožitvijo arterije delujoče ledvice se med jemanjem zaviralcev angiotenzinske konvertaze ali antagonistov angiotenzina II zveča nevarnost pojava hude hipotenzije in motnje v ledvičnem delovanju.
English: Rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.
Slovenian: Pri bolnikih, ki so jemali irbesartan so poročali o redkih primerih alergijskih kožnih reakcij (izpuščaj, koprivnica) in o lokaliziranih oteklinah obraza, ustnic in/ali jezika.
English: Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.
Slovenian: Hidroklorotiazid: na nekaj eksperimentalnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar pa dokazi niso zanesljivi.
English: There is no experience regarding the administration of Irbesartan Hydrochlorothiazide BMS in patients with a recent kidney transplantation.
Slovenian: Izkušenj z uporabo zdravila Irbesartan Hydrochlorothiazide BMS pri bolnikih po nedavni presaditvi ledvice ni.
English: Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Slovenian: Nesteroidna protivnetna zdravila: pri nekaterih bolnikih se lahko med hkratnim jemanjem nesteroidnih protivnetnih zdravil zmanjša diuretski, natriuretski in antihipertenzijski učinek tiazidnih diuretikov.
English: The PSUR cycle of Irbesartan Hydrochlorothiazide BMS is aligned with the cross-referred product, KARVEZIDE, until otherwise specified.
Slovenian: Cikel predajanja periodičnih poročil o varnosti zdravila Irbesartan Hydrochlorothiazide BMS, je vezan na referenčno zdravilo KARVEZIDE, dokler ni določeno drugače.
English: Preparations containing lithium should not be taken with Irbesartan Hydrochlorothiazide BMS without close supervision by your doctor.
Slovenian: Zdravila, ki vsebujejo litij, smete z zdravilom Irbesartan Hydrochlorothiazide BMS jemati le pod strogim zdravniških nadzorom.
English: There is no clinical experience with Irbesartan Hydrochlorothiazide BMS in patients with hepatic impairment.
Slovenian: Kliničnih izkušenj z uporabo zdravila Irbesartan Hydrochlorothiazide BMS pri bolnikih z jetrno okvaro ni.
English: Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Slovenian: Jetrna okvara: pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
English: Your doctor will instruct you how to switch from the previous treatment to Irbesartan Hydrochlorothiazide BMS.
Slovenian: Povedal vam bo tudi, kako prenehati jemati dosedanje zdravilo in kako začeti zdravljenje z zdravilom Irbesartan Hydrochlorothiazide BMS.
English: Paediatric patients: Irbesartan Hydrochlorothiazide BMS is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.
Slovenian: Otroci in mladostniki: zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba zdravila Irbesartan Hydrochlorothiazide BMS pri otrocih in mladostnikih ni priporočljiva.
English: Hepatic impairment: Irbesartan Hydrochlorothiazide BMS is not indicated in patients with severe hepatic impairment.
Slovenian: Jetrna okvara: zdravilo Irbesartan Hydrochlorothiazide BMS ni primerno za bolnike s hudo jetrno okvaro.
English: No specific information is available on the treatment of overdose with Irbesartan Hydrochlorothiazide BMS.
Slovenian: O zdravljenju posledic prevelikega odmerjanja zdravila Irbesartan Hydrochlorothiazide BMS ni specifičnih podatkov.
English: Irbesartan Hydrochlorothiazide BMS is unlikely to affect your ability to drive or use machines.
Slovenian: Možnost, da bi zdravilo Irbesartan Hydrochlorothiazide BMS vplivalo na sposobnost za upravljanje vozil in strojev je majhna.
English: Side effects reported in clinical studies for patients treated with Irbesartan Hydrochlorothiazide BMS were:
Slovenian: Med kliničnimi študijami so pri bolnikih, ki so se zdravili z zdravilom Irbesartan Hydrochlorothiazide BMS, poročali o naslednjih neželenih učinkih:
English: The two active ingredients in Irbesartan Hydrochlorothiazide BMS work together to lower blood pressure further than if either was given alone.
Slovenian: Zdravilni učinkovini v zdravilu Irbesartan Hydrochlorothiazide BMS znižujeta krvni tlak, in to še bolj kot če bi jemali vsako učinkovino posebej.
English: Medicinal products affected by serum potassium disturbances: periodic monitoring of serum potassium is recommended when Irbesartan Hydrochlorothiazide BMS is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).
Slovenian: Zdravila, na katera vpliva serumska koncentracija kalija: med hkratnim zdravljenjem z zdravilom Irbesartan Hydrochlorothiazide BMS in drugimi zdravili, na katerih delovanje vpliva serumska koncentracija kalija (npr. z digitalisovimi glikozidi, antiaritmiki), je priporočeno redno preverjanje kalija v serumu.
English: In addition to the side effects listed above, chest pain has also been reported.
Slovenian: Neželeni učinki, ki so povezani z jemanjem irbesartana samega Poleg zgoraj naštetih neželenih učinkov so poročali tudi o pojavu bolečine v prsnem košu.
English: The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3350, red, yellow and black ferric oxides, pregelatinized starch, carnauba wax.
Slovenian: Pomožne snovi so: laktoza monohidrat, mikrokristalna celuloza, premreženi natrijev karmelozat, hipromeloza, silicijev dioksid, magnezijev stearat, titanov dioksid, makrogol 3350, rdeči, rumeni in črni železov oksid, predgelirani škrob, karnauba vosek.
English: The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, red and yellow ferric oxides, carnauba wax.
Slovenian: Pomožne snovi so: laktoza monohidrat, mikrokristalna celuloza, premreženi natrijev karmelozat, hipromeloza, silicijev dioksid, magnezijev stearat, titanov dioksid, makrogol 3000, rdeči in rumeni železov oksid, karnauba vosek.
English: Hypersensitivity to the active substances, to any of the excipients (see section 6.1), or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance) Second and third trimesters of pregnancy (see sections 4.4 and 4.6) Severe renal impairment (creatinine clearance < 30 ml/min) Refractory hypokalaemia, hypercalcaemia
Slovenian: Preobčutljivost za zdravilni učinkovini ali katerokoli pomožno snov (glejte poglavje 6.1) ali druge derivate sulfonamidov (hidroklorotiazid je derivat sulfonamidov).
English: Thiazides cross the placental barrier and appear in cord blood.
Slovenian: Tiazidi prehajajo skozi posteljico in v umbilikalni obtok.
English: What Irbesartan Hydrochlorothiazide BMS contains The active substances are irbesartan and hydrochlorothiazide.
Slovenian: Kaj vsebuje zdravilo Irbesartan Hydrochlorothiazide BMS Zdravilni učinkovini sta irbesartan in hidroklorotiazid.
English: Cases of neonatal thrombocytopenia, or foetal or neonatal jaundice have been reported with maternal thiazide therapy.
Slovenian: Poročali so o primerih neonatalne trombocitopenije in fetalne ali neonatalne zlatenice pri nosečnicah, ki so jemale tiazide.
English: Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors.
Slovenian: Litij: med sočasno uporabo litija in zaviralcev angiotenzinske konvertaze so opazili reverzibilno zvečanje serumske koncentracije litija in toksičnost.
English: The other ingredients are microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica, pregelatinised maize starch, red and yellow ferric oxides (E172).
Slovenian: Pomožne snovi so: mikrokristalna celuloza, premreženi natrijev karmelozat, laktoza monohidrat, magnezijev stearat, hidratirani koloidni silicijev dioksid, predgelirani koruzni škrob, rdeči in rumeni železov oksid (E172).
English: Food does not affect the bioavailability of Irbesartan Hydrochlorothiazide BMS.
Slovenian: Sočasno uživanje hrane na biološko uporabnost zdravila Irbesartan Hydrochlorothiazide BMS ne vpliva.
English: Lactose monohydrate Microcrystalline cellulose Croscarmellose sodium Hypromellose Silicon dioxide Magnesium stearate
Slovenian: Jedro tablete: laktoza monohidrat mikrokristalna celuloza premreženi natrijev karmelozat Hipromeloza silicijev dioksid magnezijev stearat
English: INFORMATION IN BRAILLE Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg
Slovenian: PODATKI V BRAILLOVI PISAVI Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg
English: MARKETING AUTHORISATION NUMBERS EU/1/06/369/001-005
Slovenian: ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/06/369/001-005
English: MARKETING AUTHORISATION NUMBERS EU/1/06/369/017-022
Slovenian: ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/06/369/017-022
English: MARKETING AUTHORISATION NUMBERS EU/1/06/369/023-028
Slovenian: ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/06/369/023-028
English: MARKETING AUTHORISATION NUMBERS EU/1/06/369/006-010
Slovenian: ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/06/369/006-010
English: Lactose monohydrate Microcrystalline cellulose Croscarmellose sodium Pregelatinized starch Silicon dioxide Magnesium stearate Red and yellow ferric oxides
Slovenian: Jedro tablete: laktoza monohidrat mikrokristalna celuloza premreženi natrijev karmelozat Predgelirani škrob silicijev dioksid magnezijev stearat rdeči in rumeni železov oksid
English: FOR
Slovenian: Sre
English: When measured by ambulatory blood pressure monitoring, the trough to peak effects of Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg were 100%.
Slovenian: Med 24-urnim merjenjem krvnega tlaka pri bolnikih, ki so prejemali zdravilo Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg, je bilo razmerje med najmanjšim in največjim učinkom 100%.
English: Cartons of 56 x 1 film-coated tablets; 7 blister cards of 8 x 1 film-coated tablets each in PVC/PVDC/Aluminium perforated unit dose blisters.
Slovenian: Škatle s 56 x 1 filmsko obloženo tableto; 7 pretisnih omotov z 8 x 1 filmsko obloženo tableto, vsaka v perforiranem enoodmernem pretisnem omotu iz PVC/PVDC/aluminija.
English: Cartons of 56 x 1 tablets; 7 blister cards of 8 x 1 tablets each in PVC/PVDC/Aluminium perforated unit dose blisters.
Slovenian: Škatle s 56 x 1 tableto; 7 pretisnih omotov z 8 x 1 tableto, vsaka v perforiranem enoodmernem pretisnem omotu iz PVC/PVDC/aluminija.
English: MARKETING AUTHORISATION NUMBERS EU/1/06/369/011-016
Slovenian: ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/06/369/011-016
English: Although not specifically studied with the Irbesartan Hydrochlorothiazide BMS, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Slovenian: Posebnih študij z zdravilom Irbesartan Hydrochlorothiazide BMS ni, kljub temu pa povratnega zvišanja krvnega tlaka pri bolnikih, ki so jemali bodisi irbesartan bodisi hidroklorotiazid, po prenehanju jemanja zdravila niso opazili.
English: INFORMATION IN BRAILLE Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg
Slovenian: PODATKI V BRAILLOVI PISAVI Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg
English: Medicinal product subject to medical prescription
Slovenian: POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: The trough to peak effects measured by cuff during office visits were 68% and 76% for Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg and Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg, respectively.
Slovenian: Pri merjenju z manšeto v ambulanti je bilo pri bolnikih, ki so jemali zdravilo Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg, to razmerje 68%, pri tistih, ki so dobivali zdravilo Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg, pa 76%.
English: INFORMATION IN BRAILLE Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg
Slovenian: PODATKI V BRAILLOVI PISAVI Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg
English: Each film-coated tablet of Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide.
Slovenian: Ena Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg filmsko obložena tableta vsebuje 300 mg irbesartana in 25 mg hidroklorotiazida.
English: Because no information is available regarding the use of Irbesartan Hydrochlorothiazide BMS during breast-feeding, Irbesartan Hydrochlorothiazide BMS is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Slovenian: Podatkov o uporabi zdravila Irbesartan Hydrochlorothiazide BMS med dojenjem ni na voljo, zato uporaba zdravila Irbesartan Hydrochlorothiazide BMS med dojenjem ni priporočljiva.
English: Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
Slovenian: Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tablete so na voljo v pretisnih omotih s 14, 28, 56 ali 98 tabletami.
English: Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
Slovenian: Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tablete so na voljo v pretisnih omotih s 14, 28, 56 ali 98 tabletami.
English: Cartons of 84 film-coated tablets; 6 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.
Slovenian: Škatle s 84 filmsko obloženimi tabletami; 6 pretisnih omotov iz PVC/PVDC/aluminija s 14 filmsko obloženimi tabletami.
English: Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg.
Slovenian: Zdravilo Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg je namenjeno bolnikom, pri katerih se krvni tlak med zdravljenjem s 300 mg irbesartana ali z zdravilom Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg ni dovolj znižal.
English: Elderly patients: no dosage adjustment of Irbesartan Hydrochlorothiazide BMS is necessary in elderly patients.
Slovenian: Starostniki: pri starostnikih odmerka zdravila Irbesartan Hydrochlorothiazide BMS ni treba prilagajati.
English: Cartons of 98 tablets; 7 blister cards of 14 tablets in PVC/PVDC/Aluminium blisters.
Slovenian: Škatle z 98 tabletami; 7 pretisnih omotov iz PVC/PVDC/aluminija s 14 tabletami.
English: Cartons of 56 tablets; 4 blister cards of 14 tablets in PVC/PVDC/Aluminium blisters.
Slovenian: Škatle s 56 tabletami; 4 pretisni omoti iz PVC/PVDC/aluminija s 14 tabletami.
English: Cartons of 14 tablets; 1 blister card of 14 tablets in PVC/PVDC/Aluminium blisters.
Slovenian: Škatle s 14 tabletami; 1 pretisni omot iz PVC/PVDC/aluminija s 14 tabletami.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets.
Slovenian: IME ZDRAVILA Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg filmsko obložene tablete
English: Cartons of 28 tablets; 2 blister cards of 14 tablets in PVC/PVDC/Aluminium blisters.
Slovenian: Škatle z 28 tabletami; 2 pretisna omota iz PVC/PVDC/aluminija s 14 tabletami.
English: Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets are supplied in blister packs of 14, 28, 56, 84 or 98 film-coated tablets.
Slovenian: Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 56, 84 ali 98 filmsko obloženimi tabletami.
English: B.
Slovenian: V